BSE filing, BSE: 543828. Summary written from the filing by ALFA Finder's alert engine.
Sudarshan Pharma Industries Ltd: key numbers
- Share price
- ₹36.95
- Market cap
- ₹889.2 Cr
- Revenue (annual)
- ₹703.1 Cr
- Net profit (annual)
- ₹23.30 Cr
- P/E (TTM)
- 38.2×Sector 34.1×
- Promoter holding
- 57.81%-1.12% QoQ
- FII holding
- 21.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudarshan Pharma Industries Ltd
All →Sudarshan Pharma Industries Q2 FY27 Results: Net Profit ₹8.1 Cr, Up 92.9% YoY
Sudarshan Pharma Industries Ltd reported revenue from operations of ₹217 Cr (+28.5% YoY) and net profit of ₹8.1 Cr (+92.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹8.1 Cr · +92.9% YoY
Sudarshan Pharma Industries Board Meeting Date
Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.
Sudarshan Pharma Industries SME to Main Board Migration
Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.
Sudarshan Pharma Industries Other Announcement
Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sudarshan Pharma Industries Merger & Restructuring
Sudarshan Pharma terminated its proposal to acquire 9.50% of Med Therapy Biotechnology Inc. The promoters' parallel 1.50% each acquisition plan also stands terminated.
Sudarshan Pharma Industries Merger & Restructuring Worth ₹1.4 Cr
Sudarshan Pharma Industries completed the sale of its 51% stake in subsidiary Ishwari Healthcare Private Limited for ₹1.40 Crore. The entity ceases to be a subsidiary.
- Value
- ₹1.40 Cr
Other management change announcements
All →Western Overseas Study Abroad Management Change
Western Overseas Study Abroad Ltd disclosed that Non-Executive Director Mr. Deepak Kumar resigned effective 30 October 2026. The board will note the resignation, citing other work commitments.
Divgi Torqtransfer Systems Management Change
Divgi TorqTransfer Systems appointed Mr. Sarang Deshpande as Company Secretary and Compliance Officer. Ms. Ishita Kokare resigned that role effective October 30, 2026.
Religare Enterprises Management Change
Religare Enterprises appointed Ms. Dipti Jayesh Khandelwal as Company Secretary and Compliance Officer w.e.f. October 31, 2026. She was designated as a Key Managerial Personnel.
Amanta Healthcare Management Change
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Mastek Management Change
Mastek Ltd appointed Mr. Niraj Khemka as Vice President – Finance. He will also lead Investor Relations for the company.
Bharat Road Network Management Change
Ms. Ankita Rathi has resigned from her position as Company Secretary and Compliance Officer of Bharat Road Network Limited, effective from October 29, 2026.